Brolucizumab may be associated with stable VA, reduced CST in nAMD

Posted on

Treatment with brolucizumab may be associated with stable visual acuity (VA) and reduction in central subfield thickness (CST) in patients with neovascular age-related macular degeneration (nAMD), according to a study published in JAMA Ophthalmology.

In this retrospective case series, 172 eyes from 152 patients with nAMD were treated with brolucizumab IVI (6 mg). Of the 166 eyes that were not treatment naïve, 109 were switched from anti-VEGF agent due to persistent fluid. Study eyes received a mean (SD) of 1.46 (0.62) brolucizumab IVIs.

Prior to starting treatment, the mean VA and CST was a 64.1 (15.9) Early Treatment Diabetic Retinopathy Study (ETDRS) letter score and 296.7 (88.0) μm, respectively. At the end of the study, the mean VA and CST was 63.3 (17.2) and 269.8 (66.5) μm, respectively. In 14 eyes, interocular inflammation was reported; in 6 of those eyes, treatment was not needed. One previously reported eye had occlusive retinal vasculitis and severe loss of vision.

Enríquez AB, Baumal CR, Crane AM, et al. Early experience with bolucizumab treatment of neovascular age-related macular degeneration. JAMA Ophthalmol. 2021; DOI:10.1001/jamaophthalmol.2020.7085

Related Articles
Wearable collision warning device helps visually impaired individuals
Jul 22, 2021
Psoriasis linked with significantly higher risk of retinal diseases
Jul 20, 2021
Ranibizumab biosimilar has comparable efficacy, safety profile to reference product in patients with nAMD
Jul 19, 2021